Collaboration will provide handheld technology to capture patients’ perspectives on drug effects.

Quintiles and invivodata are working together to transform the way patient-reported outcomes (PRO) are used in clinical research. The aim is to reduce redundant services at every step of R&D, thus speeding up drug development.

invivodata’s PRO consulting and service solutions, along with ePRO data-capturing technology, will be coupled with the full suite of Quintiles’ clinical services. The firms believe that this will provide integrated processes and deliverables in a way that will reduce study complexity and cost. 

“Regulators, especially the FDA, have increased the pressure on drug developers to focus on the patient’s perspective regarding drug effects, and Quintiles is working with customers to effectively manage this changing environment,” notes Paula Brown Stafford, evp, integrated clinical services for Quintiles.

“While the patient perspective can be obtained in various ways, real-time PRO data are common measures of drug efficacy, and ePRO is an accurate and reliable way to capture these data. Our collaboration with invivodata will provide handheld technology that drives high patient compliance and meets the needs of the ever-evolving regulatory guidelines,” she says. 

“After a thorough evaluation, we found invivodata’s combination of science-based methodologies and innovative technology coupled with a collaborative approach to partnering in global support services to be a complement to Quintiles’ strategic vision for PRO.”

The agreement solidifies the companies’ ongoing arrangement, through which invivodata has provided its ePRO solutions in more than 20 joint studies to date. “We are very excited to formalize what has been a mutually beneficial collaborative effort over the past few years,” notes Doug Engfer, co-founder and CEO of invivodata.

“With our ongoing innovation around ePRO technology and the growing demand for our PRO consulting services, we see a nice fit into Quintiles’ approach to serving customers, and we view this relationship as a key step in driving the ePRO market forward,” Engfer states.

Previous articleStem Cell Utility Limited by Lack of Ethnic Diversity
Next articleGlobeImmune Raises $17.5M in Series E Financing